<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02843763</url>
  </required_header>
  <id_info>
    <org_study_id>API/2015/59</org_study_id>
    <nct_id>NCT02843763</nct_id>
  </id_info>
  <brief_title>Study of Specific CD4 Tumors Th1 Responses in Renal Transplant After Occurrence of Cancer</brief_title>
  <acronym>TRAK</acronym>
  <official_title>Study of Specific CD4 Tumors Th1 Responses in Renal Transplant After Occurrence of Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Hospitalier Universitaire de Besancon</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University Hospital, Lille</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University Hospital, Tours</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Centre Hospitalier Universitaire de Besancon</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      As early complications of transplantation (acute rejection and infections) were better&#xD;
      controlled and that the survival of kidney transplants has increased, chronic complications&#xD;
      of immunosuppression became increasing challenges. The incidence of cancer is greatly&#xD;
      increased in transplant and cancer is now the first cause of death. The iatrogenic&#xD;
      immunosuppression plays a major role in the increased incidence of cancer. If it is accepted&#xD;
      that the incidence of cancer is generally increased after transplantation, the increased risk&#xD;
      is very different from a specific cancer to another. Furthermore the specific treatment of&#xD;
      the tumor (surgery, radiotherapy, chemotherapy, biotherapy), the specificity of the context&#xD;
      of transplantation is related to the possibility of modulation of immunosuppression. However,&#xD;
      there is no immunological marker for predicting the effectiveness of a modification of the&#xD;
      immunosuppression.&#xD;
&#xD;
      Several studies point to the important role of CD4 T cells into Th1 anti-tumor&#xD;
      immunosurveillance group cancers. Identified &quot;helper&quot; degenerate peptides, called Universal&#xD;
      Cancer Peptide (UCP) derivative of telomerase, a type of tumor antigen universal. These UCP&#xD;
      peptides bind most HLA-DR alleles most frequent of the population and have the particularity&#xD;
      of specifically stimulate CD4 T cells of type Th1. Using a test based on the UCP, it possible&#xD;
      to detect the presence of spontaneous CD4 Th1 anti-UCP answers in several types of human&#xD;
      cancers.&#xD;
&#xD;
      The main objective of this study is to determine whether, in renal transplant patients, the&#xD;
      occurrence of cancer is associated with a deficiency of CD4 Th1 response anti-hTERT.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 13, 2016</start_date>
  <completion_date type="Anticipated">July 2021</completion_date>
  <primary_completion_date type="Anticipated">July 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Screening</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Th1 anti-hTERT cell serum levels 1A and 1B group</measure>
    <time_frame>1 day</time_frame>
    <description>Th1 anti-hTERT cell levels measured in blood by IFN-γ ELISpot in renal transplant patients developing cancer versus first with renal transplant patients without cancer.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Th1 anti-hTERT cell serum levels 1C, 2A and 2B group</measure>
    <time_frame>1 day</time_frame>
    <description>Th1anti-hTERT cell levels measured in blood by IFN-γ ELISpot in patients developing a first or recurrent squamous cell carcinoma compared with renal transplant patients without cancer.</description>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Anticipated">70</enrollment>
  <condition>Disorder Related to Renal Transplantation</condition>
  <condition>Cancer</condition>
  <arm_group>
    <arm_group_label>Renal transplant with 1rst cancer</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Renal transplant patients with first cancer (all cancer excepting skin cancer including in group 2).&#xD;
Intervention : blood sample</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Renal transplant patients without cancer</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Renal transplant patients without cancer matched for age, transplantation duration and CMV/EBV status.&#xD;
Intervention : blood sample</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Patient with cancer</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Patient with cancer from oncology departement matched for cancer type and stade and CMV/EBV status.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Renal transplant with first skin cancer</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Renal transplant patients with first epidermoid skin cancer. Intervention : blood sample</description>
  </arm_group>
  <arm_group>
    <arm_group_label>RT with several skin cancer</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Renal transplant patients with several epidermoid skin cancer. Intervention : blood sample</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Rt patients without cancer apparied to RT skin cancer</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Renal transplant patients without cancer matched for age, transplantation duration and CMV/EBV status with renal transplant patients with skin cancer.&#xD;
Intervention : blood sample</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Blood sample</intervention_name>
    <description>Blood sample (28 ml)</description>
    <arm_group_label>RT with several skin cancer</arm_group_label>
    <arm_group_label>Renal transplant patients without cancer</arm_group_label>
    <arm_group_label>Renal transplant with 1rst cancer</arm_group_label>
    <arm_group_label>Renal transplant with first skin cancer</arm_group_label>
    <arm_group_label>Rt patients without cancer apparied to RT skin cancer</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Men and women aged 18 to 80 years included&#xD;
&#xD;
          -  Signature of informed consent for participation indicating that the subject has&#xD;
             understood the purpose and procedures required by the study and agrees to participate&#xD;
             in the study and comply with the requirements and limitations inherent in this study&#xD;
&#xD;
          -  Join a French social security or receiving such a plan&#xD;
&#xD;
          -  Group 1A: renal transplant patients reporting a first cancer (all types of cancer&#xD;
             except skin inclued in group 2A or 2B)&#xD;
&#xD;
          -  Group 1B: renal transplant patients without cancer (matched to patients in group 1A)&#xD;
&#xD;
          -  1C Group: Non transplant patients reporting a first cancer (patients matched to Group&#xD;
             1A for the type and stage of cancer and the status CMV / EBV)&#xD;
&#xD;
          -  Group 2A: kidney transplant patients reporting a single squamous cell carcinoma&#xD;
&#xD;
          -  Group 2B: kidney transplant patients with multiple recurrences of squamous cell&#xD;
             carcinomas.&#xD;
&#xD;
          -  Group 2C: renal transplant patients without cancer (matched to patients in group 2A&#xD;
             and 2B)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Legal incapacity or limited legal capacity&#xD;
&#xD;
          -  Topic unlikely to cooperate in the study and / or low early cooperation by the&#xD;
             investigator&#xD;
&#xD;
          -  Without health insurance Topic&#xD;
&#xD;
          -  Pregnant woman&#xD;
&#xD;
          -  Inability to understand the reasons for the study; psychiatric disorders judged by the&#xD;
             investigator to be incompatible with the inclusion in the study&#xD;
&#xD;
          -  Active infection or not by HIV&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Didier Ducloux, Pr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Besancon University Hospital, Nephrology department</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Emilie Gaiffe, Dr.</last_name>
    <phone>0381218824</phone>
    <phone_ext>+33</phone_ext>
    <email>egaiffe@chu-besancon.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Ingrid Tissot</last_name>
    <phone>0381218427</phone>
    <phone_ext>+33</phone_ext>
    <email>itissot@chu-besancon.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Besançon University Hospital</name>
      <address>
        <city>Besançon</city>
        <zip>25030</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Emilie Gaiffe, Dr.</last_name>
      <phone>0381218824</phone>
      <phone_ext>+33</phone_ext>
      <email>egaiffe@chu-besancon.fr</email>
    </contact>
    <contact_backup>
      <last_name>Ingrid Tissot</last_name>
      <phone>0381218427</phone>
      <phone_ext>+33</phone_ext>
      <email>itissot@chu-besancon.fr</email>
    </contact_backup>
    <investigator>
      <last_name>Didier Ducloux, Pr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>January 2020</verification_date>
  <study_first_submitted>July 19, 2016</study_first_submitted>
  <study_first_submitted_qc>July 21, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 26, 2016</study_first_posted>
  <last_update_submitted>February 1, 2021</last_update_submitted>
  <last_update_submitted_qc>February 1, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 2, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

